1. Home
  2. DSGN vs PBPB Comparison

DSGN vs PBPB Comparison

Compare DSGN & PBPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSGN
  • PBPB
  • Stock Information
  • Founded
  • DSGN 2017
  • PBPB 1977
  • Country
  • DSGN United States
  • PBPB United States
  • Employees
  • DSGN N/A
  • PBPB N/A
  • Industry
  • DSGN Biotechnology: Pharmaceutical Preparations
  • PBPB Restaurants
  • Sector
  • DSGN Health Care
  • PBPB Consumer Discretionary
  • Exchange
  • DSGN Nasdaq
  • PBPB Nasdaq
  • Market Cap
  • DSGN 224.8M
  • PBPB 255.4M
  • IPO Year
  • DSGN 2021
  • PBPB 2013
  • Fundamental
  • Price
  • DSGN $3.50
  • PBPB $9.87
  • Analyst Decision
  • DSGN Hold
  • PBPB Strong Buy
  • Analyst Count
  • DSGN 1
  • PBPB 3
  • Target Price
  • DSGN $4.00
  • PBPB $15.33
  • AVG Volume (30 Days)
  • DSGN 140.5K
  • PBPB 241.5K
  • Earning Date
  • DSGN 05-07-2025
  • PBPB 05-07-2025
  • Dividend Yield
  • DSGN N/A
  • PBPB N/A
  • EPS Growth
  • DSGN N/A
  • PBPB 1009.90
  • EPS
  • DSGN N/A
  • PBPB 1.39
  • Revenue
  • DSGN N/A
  • PBPB $465,126,000.00
  • Revenue This Year
  • DSGN N/A
  • PBPB $5.17
  • Revenue Next Year
  • DSGN N/A
  • PBPB $5.58
  • P/E Ratio
  • DSGN N/A
  • PBPB $7.07
  • Revenue Growth
  • DSGN N/A
  • PBPB N/A
  • 52 Week Low
  • DSGN $2.60
  • PBPB $6.28
  • 52 Week High
  • DSGN $7.77
  • PBPB $13.48
  • Technical
  • Relative Strength Index (RSI)
  • DSGN 42.85
  • PBPB 63.83
  • Support Level
  • DSGN $3.23
  • PBPB $8.24
  • Resistance Level
  • DSGN $5.04
  • PBPB $10.61
  • Average True Range (ATR)
  • DSGN 0.48
  • PBPB 0.41
  • MACD
  • DSGN -0.05
  • PBPB 0.27
  • Stochastic Oscillator
  • DSGN 15.06
  • PBPB 74.13

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

About PBPB Potbelly Corporation

Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.

Share on Social Networks: